Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy

Y. Oshima, T. Sakamoto, T. Hisatomi, C. Tsutsumi, H. Ueno, T. Ishibashi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

This study was conducted to investigate a method of gene therapy for proliferative vitreoretinopathy (PVR) by inhibiting type β transforming growth factor (TGF-β). PVR was induced in pigmented rabbits by intravitreal injection of 50 000 rabbit conjunctival fibroblasts after vitrectomy. Subsequently, the eyes received an intravitreal application of adenovirus vector encoding a soluble type II TGF-β receptor (AdTβ-ExR, n = 10) or adenoviral vector expressing β-galactosidase (AdLacZ) (n = 10) or balanced salt solution (BSS) (n = 6). The eyes were examined ophthalmoscopically for 28 days after surgery, and the clinical stage of PVR was evaluated on a scale of zero to five. Histological examinations were performed on the treated eyes on day 28. All control eyes injected with AdLacZ or BSS developed PVR, characterized by retinal detachment and the formation of intravitreal membranes within 7 days. The eyes injected with AdTβ-ExR also developed features of PVR, but the average severity from day 5 to day 28 was significant lower than in the control eyes (P < 0.05). TGF-β plays an important role in PVR progression in a PVR model, and prevention of TGF-β signaling could be therapeutically useful.

Original languageEnglish
Pages (from-to)1214-1220
Number of pages7
JournalGene Therapy
Volume9
Issue number18
DOIs
Publication statusPublished - Sep 1 2002

Fingerprint

Proliferative Vitreoretinopathy
Growth Factor Receptors
Transforming Growth Factors
Genes
Salts
Galactosidases
Rabbits
Intravitreal Injections
Vitrectomy
Retinal Detachment
Ambulatory Surgical Procedures
Adenoviridae
Genetic Therapy
Fibroblasts
Membranes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy. / Oshima, Y.; Sakamoto, T.; Hisatomi, T.; Tsutsumi, C.; Ueno, H.; Ishibashi, T.

In: Gene Therapy, Vol. 9, No. 18, 01.09.2002, p. 1214-1220.

Research output: Contribution to journalArticle

Oshima, Y. ; Sakamoto, T. ; Hisatomi, T. ; Tsutsumi, C. ; Ueno, H. ; Ishibashi, T. / Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy. In: Gene Therapy. 2002 ; Vol. 9, No. 18. pp. 1214-1220.
@article{7c4d37ccb3714a70bb499aea706800f6,
title = "Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy",
abstract = "This study was conducted to investigate a method of gene therapy for proliferative vitreoretinopathy (PVR) by inhibiting type β transforming growth factor (TGF-β). PVR was induced in pigmented rabbits by intravitreal injection of 50 000 rabbit conjunctival fibroblasts after vitrectomy. Subsequently, the eyes received an intravitreal application of adenovirus vector encoding a soluble type II TGF-β receptor (AdTβ-ExR, n = 10) or adenoviral vector expressing β-galactosidase (AdLacZ) (n = 10) or balanced salt solution (BSS) (n = 6). The eyes were examined ophthalmoscopically for 28 days after surgery, and the clinical stage of PVR was evaluated on a scale of zero to five. Histological examinations were performed on the treated eyes on day 28. All control eyes injected with AdLacZ or BSS developed PVR, characterized by retinal detachment and the formation of intravitreal membranes within 7 days. The eyes injected with AdTβ-ExR also developed features of PVR, but the average severity from day 5 to day 28 was significant lower than in the control eyes (P < 0.05). TGF-β plays an important role in PVR progression in a PVR model, and prevention of TGF-β signaling could be therapeutically useful.",
author = "Y. Oshima and T. Sakamoto and T. Hisatomi and C. Tsutsumi and H. Ueno and T. Ishibashi",
year = "2002",
month = "9",
day = "1",
doi = "10.1038/sj.gt.3301789",
language = "English",
volume = "9",
pages = "1214--1220",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - Gene transfer of soluble TGF-β type II receptor inhibits experimental proliferative vitreoretinopathy

AU - Oshima, Y.

AU - Sakamoto, T.

AU - Hisatomi, T.

AU - Tsutsumi, C.

AU - Ueno, H.

AU - Ishibashi, T.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - This study was conducted to investigate a method of gene therapy for proliferative vitreoretinopathy (PVR) by inhibiting type β transforming growth factor (TGF-β). PVR was induced in pigmented rabbits by intravitreal injection of 50 000 rabbit conjunctival fibroblasts after vitrectomy. Subsequently, the eyes received an intravitreal application of adenovirus vector encoding a soluble type II TGF-β receptor (AdTβ-ExR, n = 10) or adenoviral vector expressing β-galactosidase (AdLacZ) (n = 10) or balanced salt solution (BSS) (n = 6). The eyes were examined ophthalmoscopically for 28 days after surgery, and the clinical stage of PVR was evaluated on a scale of zero to five. Histological examinations were performed on the treated eyes on day 28. All control eyes injected with AdLacZ or BSS developed PVR, characterized by retinal detachment and the formation of intravitreal membranes within 7 days. The eyes injected with AdTβ-ExR also developed features of PVR, but the average severity from day 5 to day 28 was significant lower than in the control eyes (P < 0.05). TGF-β plays an important role in PVR progression in a PVR model, and prevention of TGF-β signaling could be therapeutically useful.

AB - This study was conducted to investigate a method of gene therapy for proliferative vitreoretinopathy (PVR) by inhibiting type β transforming growth factor (TGF-β). PVR was induced in pigmented rabbits by intravitreal injection of 50 000 rabbit conjunctival fibroblasts after vitrectomy. Subsequently, the eyes received an intravitreal application of adenovirus vector encoding a soluble type II TGF-β receptor (AdTβ-ExR, n = 10) or adenoviral vector expressing β-galactosidase (AdLacZ) (n = 10) or balanced salt solution (BSS) (n = 6). The eyes were examined ophthalmoscopically for 28 days after surgery, and the clinical stage of PVR was evaluated on a scale of zero to five. Histological examinations were performed on the treated eyes on day 28. All control eyes injected with AdLacZ or BSS developed PVR, characterized by retinal detachment and the formation of intravitreal membranes within 7 days. The eyes injected with AdTβ-ExR also developed features of PVR, but the average severity from day 5 to day 28 was significant lower than in the control eyes (P < 0.05). TGF-β plays an important role in PVR progression in a PVR model, and prevention of TGF-β signaling could be therapeutically useful.

UR - http://www.scopus.com/inward/record.url?scp=0036740438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036740438&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301789

DO - 10.1038/sj.gt.3301789

M3 - Article

C2 - 12215888

AN - SCOPUS:0036740438

VL - 9

SP - 1214

EP - 1220

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 18

ER -